The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy
A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.
Tucatinib Extends PFS in HER2-Positive Breast Cancer, No New Safety Signals
Tucatinib demonstrated extended progression-free survival in HER2-positive breast cancer with a consistent safety profile, reinforcing its role.
Prostate Care: Balancing Immediate Relief with Long-Term Retreatment
Managing benign prostatic hyperplasia requires weighing rapid symptom improvement against the need for future interventions. Clinicians must consider patient preference and disease progression.
Half of Older Adults With Metastatic Lung Cancer Receive No Systemic Treatment
Bowhead Whale Longevity Genes Offer Clues for Cancer, Aging
Giredestrant Improves Breast Cancer Survival Regardless of Menopause
EASL 2026: Alcohol Policy Action Needed for Liver Disease
The European Health Alliance on Alcohol advocates for policy changes to mitigate alcohol-related liver disease, emphasizing the gap between clinical evidence and public health action.
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
EASL 2026 Forum: Enhancing Patient-Clinician Communication
The EASL 2026 Patient & Advocate Forum addresses critical gaps in patient-clinician communication and interprofessional collaboration.
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
Metabolic Dysfunction Associated Steatotic Liver Disease: An Overview
Vitamin K2 Supplementation May Curb Coronary Calcification
Evidence suggests vitamin K2 supplementation may reduce coronary artery calcification, a key marker of cardiovascular disease risk.
Novel Therapies Target Atherogenic Lp(a) Particle
Emerging therapeutic strategies are shifting focus from LDL cholesterol to apoB, targeting Lp(a) and other atherogenic particles.
ESC Cardio-Oncology 2026: Key Sessions and Anticipated Focus Areas
The ESC Cardio-Oncology 2026 congress will address cardiotoxicity from cancer therapies, focusing on early detection and management strategies.
Clopidogrel and Omeprazole: Re-evaluating Concomitant Use Risk
5D MRI Halves Scan Time for Congenital Heart Disease Imaging
Heat-Attributable CVD Years of Life Lost Projected to Rise Through 2050
GLP-1 Agonists Show Ocular Safety, Potential Therapeutic Role
GLP-1 receptor agonists appear safe for ocular health, with emerging evidence suggesting potential therapeutic benefits for various eye conditions.
Unapproved Retatrutide Use Challenges Clinicians
The off-label use of investigational retatrutide for weight management presents a significant challenge for clinicians, lacking robust long-term safety and efficacy data.
Medically Tailored Meals Cut HbA1c More Than Subsidies in Type 2 Diabetes
Medically tailored meals reduced HbA1c by 0.59% more than food subsidies in patients with type 2 diabetes, demonstrating superior glycemic control.
GLP-1s for Addiction: Are We There Yet?
Foundayo Confers Greater HbA1c Reduction Than Farxiga, Ozempic Pill in T2D
GLP-1 Nonresponders Often Underserved by Inadequate Dosing, Poor Adherence
Dopamine Agonists: A Fading Role in Parkinson's Treatment?
Dopamine agonists, once a cornerstone for Parkinson's disease, face increasing scrutiny due to neuropsychiatric side effects and limited long-term motor benefits.
TBI Linked Bidirectionally With Psychiatric and Neurologic Conditions
Traumatic brain injury (TBI) shows a two-way association with various psychiatric and neurologic conditions, increasing risk for both and being influenced by their presence.
ML Model Predicts Epilepsy Onset in Depression, Depression in Epilepsy
An advanced machine learning model accurately predicted the onset of depression in epilepsy patients and epilepsy in depression patients, identifying key risk factors.
New Parkinson's Drug Offers Sustained Levodopa Levels
Eptinezumab Improves Cognitive Symptoms in Migraine Patients
Cognitive Rehabilitation Eases Long-COVID Brain Fog
LymphomaNew Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
Get the full story7 min readFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
Get the full story8 min readMonoclonal Antibodies May Complicate Transfusion Testing
Get the full story7 min readBlood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections
Get the full story7 min readChemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
Get the full story8 min readPersonalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Get the full story7 min readMacrophages: Dual Role in Haematological Malignancies Explored
Get the full story7 min readMolecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
Get the full story7 min readITP Management: Bridging Clinician and Patient Perspectives
Get the full story7 min readCLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Get the full story8 min read
Systemic Lupus Erythematosus
Acne VulgarisNearly 1 in 10 With Primary Biliary Cholangitis Have CKD
AI-Assisted Fetal Echocardiography Improves Early CHD Detection
Online GLP-1 Prescriptions Often Lack Clinical Oversight
Huntington's Disease Therapy Faces Regulatory Setbacks, Clinical Impact
Wearable Devices Detect CAR-T CRS Hours Earlier, Improving Patient Outcomes
Munich, DEAug 28 – 31UpcomingEASD 2026
Madrid, ESSep 9 – 12UpcomingERS 2026
Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026
Vienna, ATOct 3 – 7UpcomingAHA 2026
Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026
Stockholm, SEJun 11 – 14PastEULAR 2026
London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30UpcomingESC 2026Munich, DEAug 28 – 31UpcomingEASD 2026Madrid, ESSep 9 – 12UpcomingERS 2026Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026Vienna, ATOct 3 – 7UpcomingAHA 2026Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026Stockholm, SEJun 11 – 14PastEULAR 2026London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
A systematic review confirms bispecific antibodies show comparable efficacy and manageable safety in relapsed/refractory multiple myeloma patients with renal impairment.
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
New insights from EHA 2026 clarify the role of iron status in erythrocytosis and symptom burden in polycythemia vera patients.
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
The ASCO 2026 May 30th program focused on immunotherapy in solid tumors, presenting data on novel combinations and biomarker-driven strategies.
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
EULAR 2026 highlights the role of autoantibodies in autoimmune rheumatic diseases, offering insights into early diagnosis and targeted therapies.
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
EHA 2026 discussions on multiple myeloma focused on integrating novel therapies into established treatment algorithms, addressing challenges in patient selection and sequence optimization.
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
EULAR 2026 will address the critical need for early, targeted intervention in psoriatic arthritis and axial spondyloarthritis to improve patient outcomes.
Immunological Insights Inform ILD & Transplant Outcomes
New immunological insights presented at ATS 2026 clarify mechanisms of interstitial lung disease progression and allograft rejection post-transplant.
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
IL-33 acts as both a pro-inflammatory cytokine and a contributor to mucus hypersecretion in COPD, complicating therapeutic targeting.
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
EHA 2026 reviewed current strategies for FLT3-mutated acute myeloid leukaemia, focusing on targeted therapies and their impact on patient outcomes.
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
EASL 2026 discussions reaffirmed peginterferon alfa as the cornerstone of HDV management, with emerging therapies showing promise.
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
Salivary galectin-9 levels are elevated in primary Sjögren's disease but do not correlate with disease activity or symptoms.
Outsmarting Shape-Shifting Lung Cancer Resistance
Resistance to EGFR inhibitors is almost inevitable, but the mechanisms are predictable and increasingly targetable. From T790M acquired resistance to osimertinib, through FLAURA2 combination strategies, Sarah Mitchell and James Carter explain how the field is staying one step ahead of lung cancer.
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
Current bispecific antibody options in relapsed/refractory DLBCL — including epcoritamab and glofitamab as T-cell engager therapies — reviewed for efficacy, safety, and sequencing after CAR-T or prior lines of therapy.
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
EHA 2026 data indicates BCMA bispecific antibodies can be integrated into community practice for relapsed/refractory multiple myeloma.
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
An expert roundtable at EHA 2026 discussed new and emerging targeted therapies for diffuse large B-cell lymphoma (DLBCL).
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
AIRSUPRA® (albuterol/budesonide) demonstrated a reduction in asthma exacerbations, addressing the need for improved rescue therapy.
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
CAR T cell therapy demonstrates promising efficacy in refractory autoimmune diseases, offering a potential new therapeutic avenue for severe cases.
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
Despite 2024 EASL guidelines for MASLD, physicians encounter significant barriers in screening and diagnosis, particularly in SEEMEA.
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
ATS 2026 highlighted epithelial cytokine pathways as a common link in severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and COPD.
EULAR 2026: Psoriatic Disease Spectrum Highlights
EULAR 2026 presentations address the broad clinical manifestations of psoriatic disease, emphasizing early diagnosis and tailored management across its diverse phenotypes.
ASCO 2026: Anticipating Advances in Oncology Treatment
ASCO 2026 is expected to highlight progress in targeted therapies, immunotherapy, and precision oncology, with a focus on biomarker-driven treatment strategies.
ATS 2026: Ultrasound Education Advances for Clinical Practice
ATS 2026 highlights advancements in ultrasound practice and instruction, addressing variability in operator proficiency and diagnostic accuracy.
How Immunotherapy Unmasks Invisible Lung Cancer
PD-L1 expression is the gatekeeper to first-line immunotherapy in NSCLC, but the biology of why some tumours respond and others do not remains one of oncology's central questions. Sarah Mitchell and James Carter examine the landmark trials that established checkpoint inhibitors as standard of care.
Epithelial Dysfunction: A Unified Target in Airway Disease Management
ATS 2026 highlights epithelial dysfunction as a central mechanism in upper and lower airway inflammation, informing evolving management strategies.
Infection Prevention Critical in Hematological Malignancies
Patients with hematological malignancies face a high risk of infection, necessitating proactive prevention strategies to improve outcomes.
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
EHA 2026 discussions highlight evolving CAR T-cell therapy guidelines for lymphoma and multiple myeloma, focusing on patient selection and sequencing.
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
New data from endo 2026 highlights patient-reported improvements in Cushing's syndrome symptoms with Korlym® (mifepristone) treatment.
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
EHA 2026 discussions focused on individualized hemophilia care, moving beyond standard prophylaxis to tailored treatment strategies based on patient-specific factors.
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
EHA 2026 highlighted real-world strategies for optimising transplant outcomes in haemoglobinopathies, focusing on conditioning and graft sources.
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
EHA 2026 session 'The Sherlock Holmes Approach' addressed diagnostic delays in rare haematological conditions, emphasizing systematic clinical reasoning.
Evolving Infection Prevention in HSCT and Cellular Therapies
Infection prevention in allogeneic HSCT and cellular therapies faces challenges from evolving pathogens and treatment modalities. New strategies are emerging.
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
EHA 2026 discussions on cytopenic myelofibrosis focused on risk stratification and treatment selection, emphasizing ruxolitinib and pacritinib.
Inluriyo™ and Verzenio® Presentations at ASCO 2026
Upcoming ASCO 2026 presentations will detail imlunestrant and abemaciclib, offering new data on endocrine therapy for breast cancer.
EHA 2026: Anticipating Advances in Haematological Malignancies
EHA 2026 is expected to feature updates on novel therapies for haematological malignancies, focusing on targeted agents and cellular therapies.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
Multiplex Assays of Variant Effects (MAVEs) offer a systematic approach to interpreting genetic variants in oncology, addressing current limitations in variant classification.
ICI Dissemination Challenges Highlighted at ASCO 2026
Global disparities in immune checkpoint inhibitor access and toxicity management were a key focus at ASCO 2026, revealing persistent implementation gaps.
CAR T: Speed and Reliability Critical for Patient Outcomes
CAR T-cell therapy for glioblastoma multiforme (GBM) requires rapid, reliable delivery to improve patient outcomes, addressing current translational limitations.
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Tile-based radiation therapy for large brain metastases was presented at ASCO 2026, offering a novel strategy for dose escalation.
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
Bispecific antibodies offer a new treatment avenue for relapsed/refractory multiple myeloma, demonstrating high response rates in heavily pretreated patients.
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
Sevabertinib, a novel tyrosine kinase inhibitor, demonstrates efficacy in advanced solid tumours, offering a new therapeutic option.
More Breast Cancer Patients Can Skip Axillary Dissection
New data presented at ASCO 2026 indicates an expanded cohort of breast cancer patients can safely omit axillary lymph node dissection.
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
CAR T-cell therapy demonstrates durable responses in relapsed/refractory large B-cell lymphoma, addressing a critical unmet need.
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Artificial intelligence applications in pulmonary medicine, presented at ATS 2026, demonstrate utility in diagnosis, prognosis, and treatment optimization.
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
Emerging CELMoD research at ASCO 2026 highlights novel therapeutic strategies for relapsed/refractory multiple myeloma, addressing evolving patient needs.
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
A novel 2L+ combination therapy demonstrates improved outcomes for adults with relapsed/refractory multiple myeloma (RRMM) after prior proteasome inhibitor (PI) and immunomodulatory agent (IMiD) exposure.
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
Review of EHA 2026 data on frontline treatment for lower-risk myelodysplastic syndromes (LR-MDS), focusing on erythroid response and transfusion independence.
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
New research from ASCO 2026 explores combination strategies for advanced cancers and a machine learning approach to immunotherapy target discovery.
EASL 2026: Alcohol Policy Action Needed for Liver Disease
The European Health Alliance on Alcohol advocates for policy changes to mitigate alcohol-related liver disease, emphasizing the gap between clinical evidence and public health action.
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
Combination therapy with ivosidenib and azacitidine significantly extends overall survival in newly diagnosed IDH1-mutant AML patients.
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
An adaptive clinical study programme for IKT-001 in Pulmonary Arterial Hypertension (PAH) was presented at ATS 2026, detailing a novel approach to trial design.
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
New data presented at EHA 2026 challenges age as the primary determinant for intensive chemotherapy eligibility in AML, advocating for comprehensive fitness assessments.
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Allogeneic cell therapy offers a targeted approach for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). This EHA 2026 review examines its role in clinical management.
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
Achieving early disease control in systemic lupus erythematosus (SLE) is critical for preventing organ damage. Targeting the interferon (IFN) pathway offers a precise therapeutic strategy.
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
New therapeutic strategies for HER2-expressing breast cancer presented at ASCO 2026 demonstrate improved outcomes across disease stages.
Multidisciplinary Care Improves Spondyloarthritis Outcomes
A multidisciplinary approach to spondyloarthritis, addressing both articular and extra-musculoskeletal manifestations, improves patient outcomes.
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
New research presented at ASCO 2025 details advances in prostate cancer, including prognostic biomarkers and precision therapies for advanced disease.
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
Managing hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) presents diagnostic and therapeutic challenges.
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Allogeneic cell therapy is a treatment option for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.
Novel Biomarkers Improve Pediatric Solid Tumor Detection
New biomarkers enhance early detection and risk stratification in pediatric solid tumors, offering potential for more targeted therapeutic strategies.
New Biologic Offers Option for Severe Eosinophilic Asthma
A new biologic agent presented at ATS 2026 provides an additional treatment option for patients with severe eosinophilic asthma.
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
Cancer therapies, while life-saving, induce significant long-term comorbidities across all age groups, necessitating integrated survivorship care.
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
Eosinophilic granulomatosis with polyangiitis (EGPA) presents diagnostic challenges; timely intervention is critical for improved patient outcomes.
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
EHA 2026 will focus on critical questions in chronic lymphocytic leukemia (CLL) care, particularly treatment selection and resistance mechanisms.
CML Survivorship: Beyond Survival to Quality of Life
Chronic myeloid leukemia (CML) management has shifted from survival to quality of life, focusing on treatment-free remission and symptom burden.
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
Advancements in Alpha-1 Antitrypsin Deficiency (AATD) focus on restoring AAT levels and achieving clinically meaningful endpoints.
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
EULAR 2026 will address the complex interplay between immune and fibrotic pathways in rheumatic diseases, offering new therapeutic avenues.
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
Molecular residual disease (MRD) detection is critical for oncology. The Oncodetect® test demonstrates analytical and clinical evidence.
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
Treat-to-target strategies in Systemic Lupus Erythematosus (SLE) aim for optimal disease control but introduce patient burden and potential risks.
CD20-Targeted Therapies Remain Central to NHL Management
CD20-directed agents continue to underpin non-Hodgkin lymphoma treatment, with ongoing refinements in antibody-drug conjugates and bispecifics.
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
Integrating AI for lung cancer prediction into multidisciplinary team workflows demonstrates operational improvements and potential for enhanced patient stratification.
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
EULAR 2026 addressed evolving concepts in systemic sclerosis, focusing on refined diagnostic criteria and prognostic indicators for earlier intervention.
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
ATS 2026 highlights advancements in nontuberculous mycobacteria (NTM) lung disease, focusing on improved detection, optimized therapy, and patient quality of life.
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
The pipeline for pediatric oncology drugs remains sparse, with most candidates failing to progress beyond early-phase trials to approval.
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Case reports from ATS 2026 detail acute respiratory failure and immune-mediated lung disease, emphasizing ventilator and extracorporeal support.
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
EASL 2026: PSC Therapies Advance Beyond Symptom Management
EASL 2026 discussions highlighted progress in primary sclerosing cholangitis (PSC) treatment, moving from symptom control to disease modification.
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
New insights into systemic lupus erythematosus (SLE) pathogenesis highlight the role of TLR7/8, with emerging therapeutic strategies.
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
Early identification of interstitial lung disease (ILD) in systemic autoimmune rheumatic diseases (SARD) and systemic sclerosis (SSc) is critical.
AI in Oncology: Practical Applications Transforming Cancer Care
AI integration in oncology is moving beyond theoretical promise to deliver tangible benefits in diagnosis, treatment planning, and patient management.
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
EULAR 2026 highlights a critical disconnect in spondyloarthritis (SpA) remission, where patient-reported symptom resolution often belies persistent subclinical inflammation.
Inflammation Drives Sickle Cell Disease Pathophysiology
Sickle cell disease (SCD) is characterised by chronic inflammation, contributing to vaso-occlusive crises and organ damage. Targeting inflammatory pathways may offer therapeutic avenues.
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
First-line venetoclax combinations versus BTK inhibitors in chronic lymphocytic leukaemia (CLL): EHA 2026 evidence on venetoclax-obinutuzumab, ibrutinib, and acalabrutinib efficacy, safety, and patient selection criteria.
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
EHA 2026 data challenges current intensive therapy strategies for AML with myelodysplasia-related changes and therapy-related AML.
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
Effective doctor-patient communication, focusing on patient self-blame, significantly increases treatment acceptance rates in cancer patients.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
ATS 2026 discussions focused on the complex etiologies and management of bronchiectasis and NTM pulmonary disease, highlighting updated guideline recommendations.
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
The ASCO 2026 May 31st program highlighted advancements in novel immunotherapies, particularly in solid tumours and haematological malignancies.
ILD Diagnosis and Management: A Practical ATS 2026 Update
ATS 2026 provided a practical framework for interstitial lung disease (ILD) diagnosis and management, emphasising multidisciplinary team approaches and early antifibrotic initiation.
RA Treatment Optimisation: Applying Two Decades of Progress
EULAR 2026 highlights the evolution of rheumatoid arthritis management, emphasising early, aggressive intervention and treat-to-target strategies.
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
Bispecific antibodies offer a new therapeutic avenue for relapsed/refractory non-Hodgkin lymphoma and multiple myeloma, demonstrating encouraging response rates.
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
New insights into systemic lupus erythematosus (SLE) pathophysiology presented at EULAR 2026 highlight pathways for targeted therapies and precision medicine.
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
EHA 2026 will review a quarter-century of molecular hematology, focusing on the integration of genomic data into targeted therapeutic strategies.
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
New insights from ATS 2026 reveal significant discrepancies between patient experiences and pulmonologist perceptions in IPF and PPF management.
Desmopressin Dosing Refined for Central Diabetes Insipidus
New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
EULAR 2026 guidelines for polymyalgia rheumatica (PMR) integrate real-world evidence (RWE), refining diagnostic and treatment algorithms.
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
ATS 2026 highlights mechanistic and multimodal approaches to obstructive sleep apnea, moving beyond CPAP to targeted therapies.
Triple Therapy Optimises COPD Outcomes at ATS 2026
ATS 2026 presentations highlight tailored triple therapy for obstructive lung disease, improving lung function and reducing exacerbations.
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
ASCO 2026 discussions underscore significant challenges in delivering equitable cancer care during crises and to immigrant and displaced populations.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
Radiopharmaceutical therapy (RPT) offers targeted cancer treatment, but challenges in efficacy, patient access, and risk mitigation persist.
Sarcoidosis: Current Understanding of Diagnosis and Management
Sarcoidosis presents a diagnostic and therapeutic challenge. This review summarises current approaches to diagnosis, staging, and treatment strategies.
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
ASCO 2026 will address cancer elimination, focusing on prevention, early detection, and treatment advancements. Current evidence suggests a multi-faceted approach is necessary.
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
ATS 2026 session addresses persistent challenges in right heart catheterization waveform interpretation, offering a structured approach to reduce diagnostic ambiguity.
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
Translating symptom science into clinical practice demonstrably improves patient outcomes in oncology, as highlighted at ASCO 2026.
Multidisciplinary Approach Improves Autoimmune ILD Management
A collaborative model involving rheumatology, radiology, and pulmonology is essential for effective autoimmune interstitial lung disease (ILD) care.
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
A new consensus statement from EASL 2026 aims to standardise the diagnosis and management of Alpha-1 Antitrypsin Deficiency (AATD) related liver disease.
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
New data presented at ASCO 2026 indicate that tafasitamab combined with R-CHOP improves outcomes for newly diagnosed DLBCL patients.
Caplacizumab Improves iTTP Outcomes in Real-World Settings
Real-world data presented at EHA 2026 confirm caplacizumab's efficacy in immune-mediated thrombotic thrombocytopenic purpura (iTTP), reducing refractory disease and mortality.
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
Belantamab mafodotin's position in relapsed/refractory multiple myeloma treatment continues to evolve, with new data presented at EHA 2026 refining its application.
Ventilator Management: Foundations for Bedside Implementation
Effective mechanical ventilation requires precise setup and liberation strategies. Practical foundations are essential for optimal patient outcomes.
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
New real-world evidence presented at ATS 2026 indicates that initiating triple therapy earlier in asthma management may improve patient outcomes.
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
The ASCO 2026 June 1st program focused on advancements in immunotherapy, particularly for solid tumours, with new data presented on combination strategies.
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
EULAR 2026 discussions highlight the need for integrated, multidisciplinary approaches to VEXAS syndrome, focusing on early diagnosis and targeted management.
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
A EULAR 2026 session addressed the diagnostic delay in axial spondyloarthritis, highlighting the need for improved GP recognition and referral pathways.
Hypercortisolism: Emerging Diagnostic and Management Insights
New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
The management of chronic lymphocytic leukemia (CLL) with BTK inhibitors is evolving, necessitating careful consideration of treatment sequencing and resistance mechanisms.
Obesity Management Improves Psoriatic Disease Outcomes
Addressing obesity in psoriatic disease patients improves dermatological and musculoskeletal outcomes, highlighting the need for integrated care strategies.
CLL First-Line Therapy: Case-Based Insights from EHA 2026
EHA 2026 session explores first-line chronic lymphocytic leukemia (CLL) therapy through interactive case studies, addressing evolving treatment paradigms.
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
BRINSUPRI® receives first approval for non-cystic fibrosis bronchiectasis (NCFB), addressing a significant unmet need in chronic respiratory care.
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.
Real-World Data Confirms Proximal Complement Inhibition in PNH
Real-world evidence presented at EHA 2026 validates the efficacy and safety of proximal complement inhibition in paroxysmal nocturnal hemoglobinuria (PNH).
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
EHA 2026 data indicates that functional fitness assessments, rather than chronological age, should guide intensive chemotherapy eligibility in AML.
NDMM Treatment Optimisation: Communication Key to Individualisation
Optimising treatment for newly-diagnosed multiple myeloma (NDMM) requires patient-centred communication to individualise therapy and improve outcomes.
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
Interactive case-based journey at EHA 2026 explores optimal integration of bispecific antibodies in follicular lymphoma management.
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
FLT3 inhibitors are increasingly critical in AML management, improving transplant eligibility and post-remission outcomes, with new combination data emerging.
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
New strategies in ANCA-associated vasculitis (GPA/MPA) focus on achieving sustained remission and preventing relapse with targeted therapies.
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
New research presented at EULAR 2026 explores upstream B-cell targeting to address primary Sjögren disease pathology, focusing on early intervention.
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
EHA 2026 explored optimal treatment sequencing for diffuse large B-cell lymphoma (DLBCL) with current therapeutic options.
Early Breast Cancer at ASCO 2026: Trials to Watch
ASCO 2026 is expected to bring pivotal data on adjuvant and neoadjuvant strategies in early breast cancer. Here is what clinicians should watch for.
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
Targeting CD19+ B-cells offers a corticosteroid-sparing strategy for IgG4-Related Disease, addressing relapse rates and long-term toxicity.
AI Foundation Models Enhance Diagnostic Insights in Oncology
AI foundation models presented at ASCO 2026 demonstrate potential to improve diagnostic precision and challenge existing oncology paradigms.
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Multi-cancer early detection (MCED) tests offer a potential strategy for earlier cancer diagnosis, particularly for cancers lacking standard screening.
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
A new study presented at ASCO 2026 demonstrates yoga significantly improves insomnia, fatigue, and anxiety in cancer survivors.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Pediatric Advanced Bronchoscopy: Precision in Airway Management
Advanced diagnostic and interventional bronchoscopy in pediatric patients offers precise airway management for complex conditions, reducing morbidity.
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
A phase II trial demonstrates improved overall survival with TACE combined with camrelizumab and rivoceranib for unresectable HCC.
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
Newly diagnosed multiple myeloma (NDMM) treatment is evolving, with quadruplet regimens demonstrating improved depth of response and progression-free survival.
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant efficacy in chronic weight management, offering a new therapeutic option.
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
Sarcomas present diagnostic and therapeutic challenges due to their heterogeneous nature. DNA methylation profiling may enhance early diagnosis and personalized treatment.
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
Understanding tumor evolution is critical for effective cancer therapy. The Human Tumor Atlas Network (HTAN) provides an ecological and evolutionary framework.
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
New data from the Summit and Apex trials demonstrate avapritinib's efficacy in systemic mastocytosis, offering a targeted treatment option.
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
Acute respiratory failure (ARF) presents distinct physiological phenotypes and trajectories across pediatric and adult populations, necessitating age-specific management.
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Cardiopulmonary exercise testing (CPET) continues to evolve, offering enhanced diagnostic and prognostic precision for various cardiopulmonary conditions. New applications presented at ATS 2026 highlight its utility beyond traditional indications.
ITP Management: Bridging Clinician and Patient Perspectives
Chronic immune thrombocytopenia (ITP) management: a clinical review aligning physician treatment strategies with patient quality-of-life priorities, long-term outcomes, and disease burden in chronic ITP.
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Meningeal lymphatic vessels (MLVs) exhibit a dual role in brain metastases, initially promoting anti-tumor immunity but later facilitating dissemination.
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
New data presented at EHA 2026 highlight emerging therapeutic strategies for chronic lymphocytic leukemia (CLL) patients progressing after covalent BTK inhibitor (cBTKi) therapy, demonstrating improved progression-free survival and response rates.
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
Rheumatoid arthritis (RA) significantly increases fracture risk beyond traditional factors. EULAR 2026 data underscores the need for early bone health assessment.
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
Emerging data from EHA 2026 highlight advancements in relapsed/refractory multiple myeloma, focusing on CAR T-cell therapies and bispecific antibodies.
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
Nerandomilast, a novel anti-inflammatory agent, demonstrates efficacy in reducing exacerbation rates in patients with moderate to severe COPD.
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
EULAR 2026 reaffirms methotrexate's central role in first-line rheumatoid arthritis therapy, with new data on optimal dosing and combination strategies.
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
BCMA-directed therapies are emerging as a critical treatment option for relapsed/refractory multiple myeloma, addressing a significant unmet need.
Pediatric Pulmonary Research Gaps Highlighted for Global Health
A review of pediatric pulmonary research emphasizes significant disparities in global health and underserved populations, underscoring critical unmet needs.
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
A new subcutaneous immunotherapy formulation provides a convenient alternative for patients, potentially reducing administration time and healthcare resource utilization.
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
YUTREPIA® (treprostinil) inhalation powder offers a new prostacyclin treatment option for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
The ASCO 2026 May 29th program focused on advancements in targeted therapies and immunotherapies across various cancer types, presenting data on efficacy and safety.
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
Extracellular vesicles (EVs) and particles (EPs) offer new avenues for cancer diagnosis, prognosis, and therapy. Their role as biomarkers and drug delivery systems is expanding.
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
Late-onset genetic cholestatic diseases are frequently missed in adults, leading to delayed diagnosis and suboptimal management. Increased awareness is critical.
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
A novel fixed-duration combination therapy with a BCL-2 inhibitor as backbone provides treatment-free intervals for patients with first-line CLL.
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
ATS 2026 discussions on severe asthma treatment highlight the need to integrate patient-reported outcomes beyond lung function, addressing quality of life.
EASL 2026 Forum: Enhancing Patient-Clinician Communication
The EASL 2026 Patient & Advocate Forum addresses critical gaps in patient-clinician communication and interprofessional collaboration.
Early Intervention in SLE/LN Reduces Long-Term Damage
Acting early in systemic lupus erythematosus (SLE) and lupus nephritis (LN) is critical for preventing irreversible organ damage and improving patient outcomes.
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
ATS 2026 highlights evolving lung cancer management, focusing on precision medicine and novel targeted therapies for improved patient outcomes.
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
ATS 2026 highlights the persistent gap in objective cough assessment in respiratory diseases, hindering precise diagnosis and treatment efficacy.
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
New data from EHA 2026 indicate that combination therapies involving JAK inhibitors may improve outcomes for myelofibrosis patients.
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
Natural killer (NK) cell-based immunotherapies are emerging as a promising cancer treatment strategy, with ongoing clinical trials exploring their efficacy.
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
EASL 2026 data indicates non-invasive markers may reduce liver biopsy necessity for MASH diagnosis, offering a less burdensome alternative.
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
Experts at EASL 2026 discussed the distinct challenges of managing advanced fibrosis in MASH, highlighting diagnostic and therapeutic complexities.
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
CAR T-cell therapy for diffuse large B-cell lymphoma (DLBCL) presents a complex treatment landscape. EHA 2026 data focuses on refining patient selection and management strategies to improve efficacy and safety.
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
TRUQAP with fulvestrant offers a second-line treatment for HR+/HER2- advanced or metastatic breast cancer with specific PI3K-AKT pathway alterations.
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Strategies for initiating and sequencing targeted therapy in CLL must align with patient priorities and evidence for long-term benefit.
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
CAR T cell therapy is emerging as a potential immune reset strategy for severe systemic lupus erythematosus and systemic sclerosis, offering a new therapeutic avenue.
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
New insights from EULAR 2026 highlight the critical role of early diagnosis and optimised management strategies in reducing the disease burden of axial spondyloarthritis (axSpA).
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
Understanding immune drivers in autoimmune cytopenias, discussed at EHA 2026, offers insights into targeted therapies and improved patient management.
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
New insights at EULAR 2026 highlight the need to address objective disease activity in Sjögren’s, moving beyond symptomatic management.
Infection Prevention Critical in Hematological Malignancies
Infections remain a leading cause of morbidity and mortality in hematological malignancy patients. Prophylactic strategies are essential.
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
Myriad's Precise MRD™ test offers ultra-sensitive molecular residual disease detection, potentially guiding adjuvant therapy decisions.
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
Acute myeloid leukemia (AML) presents significant treatment challenges. This review explores current strategies to improve patient outcomes.
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
Optimising first-line treatment for haematologic malignancies requires balancing continuous and fixed-duration therapies, with Measurable Residual Disease (MRD) status emerging as a critical determinant.
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
EULAR 2026 highlights the imperative of early diagnosis and intervention in inflammatory joint diseases and osteoporosis to prevent irreversible damage.
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
ATS 2026 will feature a hands-on guide to basic bronchoscopy, EBUS, and guided bronchoscopy, addressing the need for advanced procedural competency.
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
Subcutaneous CD38 monoclonal antibody administration in quad therapy for multiple myeloma significantly reduces treatment burden and improves patient experience.
RA Care: Navigating Treatment Choices at EULAR 2026
Rheumatoid arthritis management requires precise treatment selection. EULAR 2026 highlights the ongoing challenge of optimising therapy.
Lupus Management: Progress and Persistent Challenges at EULAR 2026
Systemic lupus erythematosus (SLE) remains a complex autoimmune disease with significant unmet needs despite therapeutic advancements. EULAR 2026 will review current progress and future directions.
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
Multiple myeloma treatment faces challenges with resistance. New strategies presented at EHA 2026 offer insights into overcoming these hurdles.
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
Alpha-1 antitrypsin (AAT) protein extends its protective role beyond established AAT deficiency, influencing general lung health.
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
The EHA 2026 session addresses the immediate need for hematologists to integrate AI tools ethically and practically into clinical workflows.
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
The Phase 3 PEAK study demonstrated improved progression-free survival with a novel therapeutic agent in advanced gastrointestinal stromal tumors (GIST).
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Next-generation sleep diagnostics, integrating AI, wearables, and sensors, promise to redefine the care continuum for sleep disorders, moving beyond traditional polysomnography.
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
EHA 2026 discussions highlight persistent challenges in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) management, focusing on optimal sequencing and novel agent integration.
XLH Management: Rheumatology Must Adapt at EULAR 2026
Current rheumatology approaches for rare bone diseases like X-linked hypophosphatemia (XLH) require re-evaluation. EULAR 2026 presents an opportunity to integrate multidisciplinary care models.
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
Chemotherapy-free regimens for pediatric acute promyelocytic leukemia (APL) demonstrate superior efficacy and reduced toxicity compared to traditional chemotherapy.
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
EASL 2026 highlights the evolving role of non-invasive diagnostics in liver disease, offering improved accuracy for fibrosis and steatosis assessment.
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
EULAR 2026 highlights the critical role of rapid disease control in systemic lupus erythematosus (SLE) to mitigate irreversible organ damage.
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
Bispecific antibodies offer new options for relapsed/refractory follicular lymphoma, particularly after two prior lines of therapy.
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
New A-TANGO organ failure score refines acute-on-chronic liver failure (ACLF) diagnosis and prognostication in hospitalised cirrhosis patients.
Macrophages: Dual Role in Haematological Malignancies Explored
Macrophages exhibit a dual role in haematological malignancies, acting as both tumour suppressors and promoters, influencing disease progression and therapeutic responses.
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
A systematic review confirms bispecific antibodies show comparable efficacy and manageable safety in relapsed/refractory multiple myeloma patients with renal impairment.
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
New insights from EHA 2026 clarify the role of iron status in erythrocytosis and symptom burden in polycythemia vera patients.
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
The ASCO 2026 May 30th program focused on immunotherapy in solid tumors, presenting data on novel combinations and biomarker-driven strategies.
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
EULAR 2026 highlights the role of autoantibodies in autoimmune rheumatic diseases, offering insights into early diagnosis and targeted therapies.
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
EHA 2026 discussions on multiple myeloma focused on integrating novel therapies into established treatment algorithms, addressing challenges in patient selection and sequence optimization.
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
EULAR 2026 will address the critical need for early, targeted intervention in psoriatic arthritis and axial spondyloarthritis to improve patient outcomes.
Immunological Insights Inform ILD & Transplant Outcomes
New immunological insights presented at ATS 2026 clarify mechanisms of interstitial lung disease progression and allograft rejection post-transplant.
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
IL-33 acts as both a pro-inflammatory cytokine and a contributor to mucus hypersecretion in COPD, complicating therapeutic targeting.
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
EHA 2026 reviewed current strategies for FLT3-mutated acute myeloid leukaemia, focusing on targeted therapies and their impact on patient outcomes.
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
EASL 2026 discussions reaffirmed peginterferon alfa as the cornerstone of HDV management, with emerging therapies showing promise.
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
Salivary galectin-9 levels are elevated in primary Sjögren's disease but do not correlate with disease activity or symptoms.
Outsmarting Shape-Shifting Lung Cancer Resistance
Resistance to EGFR inhibitors is almost inevitable, but the mechanisms are predictable and increasingly targetable. From T790M acquired resistance to osimertinib, through FLAURA2 combination strategies, Sarah Mitchell and James Carter explain how the field is staying one step ahead of lung cancer.
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
Current bispecific antibody options in relapsed/refractory DLBCL — including epcoritamab and glofitamab as T-cell engager therapies — reviewed for efficacy, safety, and sequencing after CAR-T or prior lines of therapy.
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
EHA 2026 data indicates BCMA bispecific antibodies can be integrated into community practice for relapsed/refractory multiple myeloma.
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
An expert roundtable at EHA 2026 discussed new and emerging targeted therapies for diffuse large B-cell lymphoma (DLBCL).
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
AIRSUPRA® (albuterol/budesonide) demonstrated a reduction in asthma exacerbations, addressing the need for improved rescue therapy.
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
CAR T cell therapy demonstrates promising efficacy in refractory autoimmune diseases, offering a potential new therapeutic avenue for severe cases.
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
Despite 2024 EASL guidelines for MASLD, physicians encounter significant barriers in screening and diagnosis, particularly in SEEMEA.
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
ATS 2026 highlighted epithelial cytokine pathways as a common link in severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and COPD.
EULAR 2026: Psoriatic Disease Spectrum Highlights
EULAR 2026 presentations address the broad clinical manifestations of psoriatic disease, emphasizing early diagnosis and tailored management across its diverse phenotypes.
ASCO 2026: Anticipating Advances in Oncology Treatment
ASCO 2026 is expected to highlight progress in targeted therapies, immunotherapy, and precision oncology, with a focus on biomarker-driven treatment strategies.
ATS 2026: Ultrasound Education Advances for Clinical Practice
ATS 2026 highlights advancements in ultrasound practice and instruction, addressing variability in operator proficiency and diagnostic accuracy.
How Immunotherapy Unmasks Invisible Lung Cancer
PD-L1 expression is the gatekeeper to first-line immunotherapy in NSCLC, but the biology of why some tumours respond and others do not remains one of oncology's central questions. Sarah Mitchell and James Carter examine the landmark trials that established checkpoint inhibitors as standard of care.
Epithelial Dysfunction: A Unified Target in Airway Disease Management
ATS 2026 highlights epithelial dysfunction as a central mechanism in upper and lower airway inflammation, informing evolving management strategies.
Infection Prevention Critical in Hematological Malignancies
Patients with hematological malignancies face a high risk of infection, necessitating proactive prevention strategies to improve outcomes.
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
EHA 2026 discussions highlight evolving CAR T-cell therapy guidelines for lymphoma and multiple myeloma, focusing on patient selection and sequencing.
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
New data from endo 2026 highlights patient-reported improvements in Cushing's syndrome symptoms with Korlym® (mifepristone) treatment.
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
EHA 2026 discussions focused on individualized hemophilia care, moving beyond standard prophylaxis to tailored treatment strategies based on patient-specific factors.
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
EHA 2026 highlighted real-world strategies for optimising transplant outcomes in haemoglobinopathies, focusing on conditioning and graft sources.
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
EHA 2026 session 'The Sherlock Holmes Approach' addressed diagnostic delays in rare haematological conditions, emphasizing systematic clinical reasoning.
Evolving Infection Prevention in HSCT and Cellular Therapies
Infection prevention in allogeneic HSCT and cellular therapies faces challenges from evolving pathogens and treatment modalities. New strategies are emerging.
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
EHA 2026 discussions on cytopenic myelofibrosis focused on risk stratification and treatment selection, emphasizing ruxolitinib and pacritinib.
Inluriyo™ and Verzenio® Presentations at ASCO 2026
Upcoming ASCO 2026 presentations will detail imlunestrant and abemaciclib, offering new data on endocrine therapy for breast cancer.
EHA 2026: Anticipating Advances in Haematological Malignancies
EHA 2026 is expected to feature updates on novel therapies for haematological malignancies, focusing on targeted agents and cellular therapies.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
Multiplex Assays of Variant Effects (MAVEs) offer a systematic approach to interpreting genetic variants in oncology, addressing current limitations in variant classification.
ICI Dissemination Challenges Highlighted at ASCO 2026
Global disparities in immune checkpoint inhibitor access and toxicity management were a key focus at ASCO 2026, revealing persistent implementation gaps.
CAR T: Speed and Reliability Critical for Patient Outcomes
CAR T-cell therapy for glioblastoma multiforme (GBM) requires rapid, reliable delivery to improve patient outcomes, addressing current translational limitations.
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Tile-based radiation therapy for large brain metastases was presented at ASCO 2026, offering a novel strategy for dose escalation.
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
Bispecific antibodies offer a new treatment avenue for relapsed/refractory multiple myeloma, demonstrating high response rates in heavily pretreated patients.
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
Sevabertinib, a novel tyrosine kinase inhibitor, demonstrates efficacy in advanced solid tumours, offering a new therapeutic option.
More Breast Cancer Patients Can Skip Axillary Dissection
New data presented at ASCO 2026 indicates an expanded cohort of breast cancer patients can safely omit axillary lymph node dissection.
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
CAR T-cell therapy demonstrates durable responses in relapsed/refractory large B-cell lymphoma, addressing a critical unmet need.
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Artificial intelligence applications in pulmonary medicine, presented at ATS 2026, demonstrate utility in diagnosis, prognosis, and treatment optimization.
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
Emerging CELMoD research at ASCO 2026 highlights novel therapeutic strategies for relapsed/refractory multiple myeloma, addressing evolving patient needs.
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
A novel 2L+ combination therapy demonstrates improved outcomes for adults with relapsed/refractory multiple myeloma (RRMM) after prior proteasome inhibitor (PI) and immunomodulatory agent (IMiD) exposure.
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
Review of EHA 2026 data on frontline treatment for lower-risk myelodysplastic syndromes (LR-MDS), focusing on erythroid response and transfusion independence.
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
New research from ASCO 2026 explores combination strategies for advanced cancers and a machine learning approach to immunotherapy target discovery.
EASL 2026: Alcohol Policy Action Needed for Liver Disease
The European Health Alliance on Alcohol advocates for policy changes to mitigate alcohol-related liver disease, emphasizing the gap between clinical evidence and public health action.
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
Combination therapy with ivosidenib and azacitidine significantly extends overall survival in newly diagnosed IDH1-mutant AML patients.
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
An adaptive clinical study programme for IKT-001 in Pulmonary Arterial Hypertension (PAH) was presented at ATS 2026, detailing a novel approach to trial design.
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
New data presented at EHA 2026 challenges age as the primary determinant for intensive chemotherapy eligibility in AML, advocating for comprehensive fitness assessments.
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Allogeneic cell therapy offers a targeted approach for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). This EHA 2026 review examines its role in clinical management.
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
Achieving early disease control in systemic lupus erythematosus (SLE) is critical for preventing organ damage. Targeting the interferon (IFN) pathway offers a precise therapeutic strategy.
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
New therapeutic strategies for HER2-expressing breast cancer presented at ASCO 2026 demonstrate improved outcomes across disease stages.
Multidisciplinary Care Improves Spondyloarthritis Outcomes
A multidisciplinary approach to spondyloarthritis, addressing both articular and extra-musculoskeletal manifestations, improves patient outcomes.
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
New research presented at ASCO 2025 details advances in prostate cancer, including prognostic biomarkers and precision therapies for advanced disease.
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
Managing hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) presents diagnostic and therapeutic challenges.
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Allogeneic cell therapy is a treatment option for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.
Novel Biomarkers Improve Pediatric Solid Tumor Detection
New biomarkers enhance early detection and risk stratification in pediatric solid tumors, offering potential for more targeted therapeutic strategies.
New Biologic Offers Option for Severe Eosinophilic Asthma
A new biologic agent presented at ATS 2026 provides an additional treatment option for patients with severe eosinophilic asthma.
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
Cancer therapies, while life-saving, induce significant long-term comorbidities across all age groups, necessitating integrated survivorship care.
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
Eosinophilic granulomatosis with polyangiitis (EGPA) presents diagnostic challenges; timely intervention is critical for improved patient outcomes.
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
EHA 2026 will focus on critical questions in chronic lymphocytic leukemia (CLL) care, particularly treatment selection and resistance mechanisms.
CML Survivorship: Beyond Survival to Quality of Life
Chronic myeloid leukemia (CML) management has shifted from survival to quality of life, focusing on treatment-free remission and symptom burden.
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
Advancements in Alpha-1 Antitrypsin Deficiency (AATD) focus on restoring AAT levels and achieving clinically meaningful endpoints.
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
EULAR 2026 will address the complex interplay between immune and fibrotic pathways in rheumatic diseases, offering new therapeutic avenues.
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
Molecular residual disease (MRD) detection is critical for oncology. The Oncodetect® test demonstrates analytical and clinical evidence.
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
Treat-to-target strategies in Systemic Lupus Erythematosus (SLE) aim for optimal disease control but introduce patient burden and potential risks.
CD20-Targeted Therapies Remain Central to NHL Management
CD20-directed agents continue to underpin non-Hodgkin lymphoma treatment, with ongoing refinements in antibody-drug conjugates and bispecifics.
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
Integrating AI for lung cancer prediction into multidisciplinary team workflows demonstrates operational improvements and potential for enhanced patient stratification.
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
EULAR 2026 addressed evolving concepts in systemic sclerosis, focusing on refined diagnostic criteria and prognostic indicators for earlier intervention.
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
ATS 2026 highlights advancements in nontuberculous mycobacteria (NTM) lung disease, focusing on improved detection, optimized therapy, and patient quality of life.
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
The pipeline for pediatric oncology drugs remains sparse, with most candidates failing to progress beyond early-phase trials to approval.
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Case reports from ATS 2026 detail acute respiratory failure and immune-mediated lung disease, emphasizing ventilator and extracorporeal support.
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
EASL 2026: PSC Therapies Advance Beyond Symptom Management
EASL 2026 discussions highlighted progress in primary sclerosing cholangitis (PSC) treatment, moving from symptom control to disease modification.
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
New insights into systemic lupus erythematosus (SLE) pathogenesis highlight the role of TLR7/8, with emerging therapeutic strategies.
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
Early identification of interstitial lung disease (ILD) in systemic autoimmune rheumatic diseases (SARD) and systemic sclerosis (SSc) is critical.
AI in Oncology: Practical Applications Transforming Cancer Care
AI integration in oncology is moving beyond theoretical promise to deliver tangible benefits in diagnosis, treatment planning, and patient management.
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
EULAR 2026 highlights a critical disconnect in spondyloarthritis (SpA) remission, where patient-reported symptom resolution often belies persistent subclinical inflammation.
Inflammation Drives Sickle Cell Disease Pathophysiology
Sickle cell disease (SCD) is characterised by chronic inflammation, contributing to vaso-occlusive crises and organ damage. Targeting inflammatory pathways may offer therapeutic avenues.
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
First-line venetoclax combinations versus BTK inhibitors in chronic lymphocytic leukaemia (CLL): EHA 2026 evidence on venetoclax-obinutuzumab, ibrutinib, and acalabrutinib efficacy, safety, and patient selection criteria.
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
EHA 2026 data challenges current intensive therapy strategies for AML with myelodysplasia-related changes and therapy-related AML.
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
Effective doctor-patient communication, focusing on patient self-blame, significantly increases treatment acceptance rates in cancer patients.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
ATS 2026 discussions focused on the complex etiologies and management of bronchiectasis and NTM pulmonary disease, highlighting updated guideline recommendations.
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
The ASCO 2026 May 31st program highlighted advancements in novel immunotherapies, particularly in solid tumours and haematological malignancies.
ILD Diagnosis and Management: A Practical ATS 2026 Update
ATS 2026 provided a practical framework for interstitial lung disease (ILD) diagnosis and management, emphasising multidisciplinary team approaches and early antifibrotic initiation.
RA Treatment Optimisation: Applying Two Decades of Progress
EULAR 2026 highlights the evolution of rheumatoid arthritis management, emphasising early, aggressive intervention and treat-to-target strategies.
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
Bispecific antibodies offer a new therapeutic avenue for relapsed/refractory non-Hodgkin lymphoma and multiple myeloma, demonstrating encouraging response rates.
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
New insights into systemic lupus erythematosus (SLE) pathophysiology presented at EULAR 2026 highlight pathways for targeted therapies and precision medicine.
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
EHA 2026 will review a quarter-century of molecular hematology, focusing on the integration of genomic data into targeted therapeutic strategies.
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
New insights from ATS 2026 reveal significant discrepancies between patient experiences and pulmonologist perceptions in IPF and PPF management.
Desmopressin Dosing Refined for Central Diabetes Insipidus
New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
EULAR 2026 guidelines for polymyalgia rheumatica (PMR) integrate real-world evidence (RWE), refining diagnostic and treatment algorithms.
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
ATS 2026 highlights mechanistic and multimodal approaches to obstructive sleep apnea, moving beyond CPAP to targeted therapies.
Triple Therapy Optimises COPD Outcomes at ATS 2026
ATS 2026 presentations highlight tailored triple therapy for obstructive lung disease, improving lung function and reducing exacerbations.
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
ASCO 2026 discussions underscore significant challenges in delivering equitable cancer care during crises and to immigrant and displaced populations.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
Radiopharmaceutical therapy (RPT) offers targeted cancer treatment, but challenges in efficacy, patient access, and risk mitigation persist.
Sarcoidosis: Current Understanding of Diagnosis and Management
Sarcoidosis presents a diagnostic and therapeutic challenge. This review summarises current approaches to diagnosis, staging, and treatment strategies.
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
ASCO 2026 will address cancer elimination, focusing on prevention, early detection, and treatment advancements. Current evidence suggests a multi-faceted approach is necessary.
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
ATS 2026 session addresses persistent challenges in right heart catheterization waveform interpretation, offering a structured approach to reduce diagnostic ambiguity.
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
Translating symptom science into clinical practice demonstrably improves patient outcomes in oncology, as highlighted at ASCO 2026.
Multidisciplinary Approach Improves Autoimmune ILD Management
A collaborative model involving rheumatology, radiology, and pulmonology is essential for effective autoimmune interstitial lung disease (ILD) care.
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
A new consensus statement from EASL 2026 aims to standardise the diagnosis and management of Alpha-1 Antitrypsin Deficiency (AATD) related liver disease.
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
New data presented at ASCO 2026 indicate that tafasitamab combined with R-CHOP improves outcomes for newly diagnosed DLBCL patients.
Caplacizumab Improves iTTP Outcomes in Real-World Settings
Real-world data presented at EHA 2026 confirm caplacizumab's efficacy in immune-mediated thrombotic thrombocytopenic purpura (iTTP), reducing refractory disease and mortality.
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
Belantamab mafodotin's position in relapsed/refractory multiple myeloma treatment continues to evolve, with new data presented at EHA 2026 refining its application.
Ventilator Management: Foundations for Bedside Implementation
Effective mechanical ventilation requires precise setup and liberation strategies. Practical foundations are essential for optimal patient outcomes.
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
New real-world evidence presented at ATS 2026 indicates that initiating triple therapy earlier in asthma management may improve patient outcomes.
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
The ASCO 2026 June 1st program focused on advancements in immunotherapy, particularly for solid tumours, with new data presented on combination strategies.
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
EULAR 2026 discussions highlight the need for integrated, multidisciplinary approaches to VEXAS syndrome, focusing on early diagnosis and targeted management.
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
A EULAR 2026 session addressed the diagnostic delay in axial spondyloarthritis, highlighting the need for improved GP recognition and referral pathways.
Hypercortisolism: Emerging Diagnostic and Management Insights
New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
The management of chronic lymphocytic leukemia (CLL) with BTK inhibitors is evolving, necessitating careful consideration of treatment sequencing and resistance mechanisms.
Obesity Management Improves Psoriatic Disease Outcomes
Addressing obesity in psoriatic disease patients improves dermatological and musculoskeletal outcomes, highlighting the need for integrated care strategies.
CLL First-Line Therapy: Case-Based Insights from EHA 2026
EHA 2026 session explores first-line chronic lymphocytic leukemia (CLL) therapy through interactive case studies, addressing evolving treatment paradigms.
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
BRINSUPRI® receives first approval for non-cystic fibrosis bronchiectasis (NCFB), addressing a significant unmet need in chronic respiratory care.
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.
Real-World Data Confirms Proximal Complement Inhibition in PNH
Real-world evidence presented at EHA 2026 validates the efficacy and safety of proximal complement inhibition in paroxysmal nocturnal hemoglobinuria (PNH).
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
EHA 2026 data indicates that functional fitness assessments, rather than chronological age, should guide intensive chemotherapy eligibility in AML.
NDMM Treatment Optimisation: Communication Key to Individualisation
Optimising treatment for newly-diagnosed multiple myeloma (NDMM) requires patient-centred communication to individualise therapy and improve outcomes.
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
Interactive case-based journey at EHA 2026 explores optimal integration of bispecific antibodies in follicular lymphoma management.
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
FLT3 inhibitors are increasingly critical in AML management, improving transplant eligibility and post-remission outcomes, with new combination data emerging.
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
New strategies in ANCA-associated vasculitis (GPA/MPA) focus on achieving sustained remission and preventing relapse with targeted therapies.
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
New research presented at EULAR 2026 explores upstream B-cell targeting to address primary Sjögren disease pathology, focusing on early intervention.
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
EHA 2026 explored optimal treatment sequencing for diffuse large B-cell lymphoma (DLBCL) with current therapeutic options.
Early Breast Cancer at ASCO 2026: Trials to Watch
ASCO 2026 is expected to bring pivotal data on adjuvant and neoadjuvant strategies in early breast cancer. Here is what clinicians should watch for.
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
Targeting CD19+ B-cells offers a corticosteroid-sparing strategy for IgG4-Related Disease, addressing relapse rates and long-term toxicity.
AI Foundation Models Enhance Diagnostic Insights in Oncology
AI foundation models presented at ASCO 2026 demonstrate potential to improve diagnostic precision and challenge existing oncology paradigms.
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Multi-cancer early detection (MCED) tests offer a potential strategy for earlier cancer diagnosis, particularly for cancers lacking standard screening.
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
A new study presented at ASCO 2026 demonstrates yoga significantly improves insomnia, fatigue, and anxiety in cancer survivors.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Pediatric Advanced Bronchoscopy: Precision in Airway Management
Advanced diagnostic and interventional bronchoscopy in pediatric patients offers precise airway management for complex conditions, reducing morbidity.
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
A phase II trial demonstrates improved overall survival with TACE combined with camrelizumab and rivoceranib for unresectable HCC.
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
Newly diagnosed multiple myeloma (NDMM) treatment is evolving, with quadruplet regimens demonstrating improved depth of response and progression-free survival.
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant efficacy in chronic weight management, offering a new therapeutic option.
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
Sarcomas present diagnostic and therapeutic challenges due to their heterogeneous nature. DNA methylation profiling may enhance early diagnosis and personalized treatment.
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
Understanding tumor evolution is critical for effective cancer therapy. The Human Tumor Atlas Network (HTAN) provides an ecological and evolutionary framework.
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
New data from the Summit and Apex trials demonstrate avapritinib's efficacy in systemic mastocytosis, offering a targeted treatment option.
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
Acute respiratory failure (ARF) presents distinct physiological phenotypes and trajectories across pediatric and adult populations, necessitating age-specific management.
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Cardiopulmonary exercise testing (CPET) continues to evolve, offering enhanced diagnostic and prognostic precision for various cardiopulmonary conditions. New applications presented at ATS 2026 highlight its utility beyond traditional indications.
ITP Management: Bridging Clinician and Patient Perspectives
Chronic immune thrombocytopenia (ITP) management: a clinical review aligning physician treatment strategies with patient quality-of-life priorities, long-term outcomes, and disease burden in chronic ITP.
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Meningeal lymphatic vessels (MLVs) exhibit a dual role in brain metastases, initially promoting anti-tumor immunity but later facilitating dissemination.
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
New data presented at EHA 2026 highlight emerging therapeutic strategies for chronic lymphocytic leukemia (CLL) patients progressing after covalent BTK inhibitor (cBTKi) therapy, demonstrating improved progression-free survival and response rates.
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
Rheumatoid arthritis (RA) significantly increases fracture risk beyond traditional factors. EULAR 2026 data underscores the need for early bone health assessment.
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
Emerging data from EHA 2026 highlight advancements in relapsed/refractory multiple myeloma, focusing on CAR T-cell therapies and bispecific antibodies.
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
Nerandomilast, a novel anti-inflammatory agent, demonstrates efficacy in reducing exacerbation rates in patients with moderate to severe COPD.
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
EULAR 2026 reaffirms methotrexate's central role in first-line rheumatoid arthritis therapy, with new data on optimal dosing and combination strategies.
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
BCMA-directed therapies are emerging as a critical treatment option for relapsed/refractory multiple myeloma, addressing a significant unmet need.
Pediatric Pulmonary Research Gaps Highlighted for Global Health
A review of pediatric pulmonary research emphasizes significant disparities in global health and underserved populations, underscoring critical unmet needs.
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
A new subcutaneous immunotherapy formulation provides a convenient alternative for patients, potentially reducing administration time and healthcare resource utilization.
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
YUTREPIA® (treprostinil) inhalation powder offers a new prostacyclin treatment option for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
The ASCO 2026 May 29th program focused on advancements in targeted therapies and immunotherapies across various cancer types, presenting data on efficacy and safety.
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
Extracellular vesicles (EVs) and particles (EPs) offer new avenues for cancer diagnosis, prognosis, and therapy. Their role as biomarkers and drug delivery systems is expanding.
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
Late-onset genetic cholestatic diseases are frequently missed in adults, leading to delayed diagnosis and suboptimal management. Increased awareness is critical.
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
A novel fixed-duration combination therapy with a BCL-2 inhibitor as backbone provides treatment-free intervals for patients with first-line CLL.
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
ATS 2026 discussions on severe asthma treatment highlight the need to integrate patient-reported outcomes beyond lung function, addressing quality of life.
EASL 2026 Forum: Enhancing Patient-Clinician Communication
The EASL 2026 Patient & Advocate Forum addresses critical gaps in patient-clinician communication and interprofessional collaboration.
Early Intervention in SLE/LN Reduces Long-Term Damage
Acting early in systemic lupus erythematosus (SLE) and lupus nephritis (LN) is critical for preventing irreversible organ damage and improving patient outcomes.
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
ATS 2026 highlights evolving lung cancer management, focusing on precision medicine and novel targeted therapies for improved patient outcomes.
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
ATS 2026 highlights the persistent gap in objective cough assessment in respiratory diseases, hindering precise diagnosis and treatment efficacy.
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
New data from EHA 2026 indicate that combination therapies involving JAK inhibitors may improve outcomes for myelofibrosis patients.
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
Natural killer (NK) cell-based immunotherapies are emerging as a promising cancer treatment strategy, with ongoing clinical trials exploring their efficacy.
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
EASL 2026 data indicates non-invasive markers may reduce liver biopsy necessity for MASH diagnosis, offering a less burdensome alternative.
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
Experts at EASL 2026 discussed the distinct challenges of managing advanced fibrosis in MASH, highlighting diagnostic and therapeutic complexities.
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
CAR T-cell therapy for diffuse large B-cell lymphoma (DLBCL) presents a complex treatment landscape. EHA 2026 data focuses on refining patient selection and management strategies to improve efficacy and safety.
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
TRUQAP with fulvestrant offers a second-line treatment for HR+/HER2- advanced or metastatic breast cancer with specific PI3K-AKT pathway alterations.
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Strategies for initiating and sequencing targeted therapy in CLL must align with patient priorities and evidence for long-term benefit.
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
CAR T cell therapy is emerging as a potential immune reset strategy for severe systemic lupus erythematosus and systemic sclerosis, offering a new therapeutic avenue.
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
New insights from EULAR 2026 highlight the critical role of early diagnosis and optimised management strategies in reducing the disease burden of axial spondyloarthritis (axSpA).
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
Understanding immune drivers in autoimmune cytopenias, discussed at EHA 2026, offers insights into targeted therapies and improved patient management.
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
New insights at EULAR 2026 highlight the need to address objective disease activity in Sjögren’s, moving beyond symptomatic management.
Infection Prevention Critical in Hematological Malignancies
Infections remain a leading cause of morbidity and mortality in hematological malignancy patients. Prophylactic strategies are essential.
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
Myriad's Precise MRD™ test offers ultra-sensitive molecular residual disease detection, potentially guiding adjuvant therapy decisions.
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
Acute myeloid leukemia (AML) presents significant treatment challenges. This review explores current strategies to improve patient outcomes.
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
Optimising first-line treatment for haematologic malignancies requires balancing continuous and fixed-duration therapies, with Measurable Residual Disease (MRD) status emerging as a critical determinant.
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
EULAR 2026 highlights the imperative of early diagnosis and intervention in inflammatory joint diseases and osteoporosis to prevent irreversible damage.
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
ATS 2026 will feature a hands-on guide to basic bronchoscopy, EBUS, and guided bronchoscopy, addressing the need for advanced procedural competency.
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
Subcutaneous CD38 monoclonal antibody administration in quad therapy for multiple myeloma significantly reduces treatment burden and improves patient experience.
RA Care: Navigating Treatment Choices at EULAR 2026
Rheumatoid arthritis management requires precise treatment selection. EULAR 2026 highlights the ongoing challenge of optimising therapy.
Lupus Management: Progress and Persistent Challenges at EULAR 2026
Systemic lupus erythematosus (SLE) remains a complex autoimmune disease with significant unmet needs despite therapeutic advancements. EULAR 2026 will review current progress and future directions.
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
Multiple myeloma treatment faces challenges with resistance. New strategies presented at EHA 2026 offer insights into overcoming these hurdles.
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
Alpha-1 antitrypsin (AAT) protein extends its protective role beyond established AAT deficiency, influencing general lung health.
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
The EHA 2026 session addresses the immediate need for hematologists to integrate AI tools ethically and practically into clinical workflows.
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
The Phase 3 PEAK study demonstrated improved progression-free survival with a novel therapeutic agent in advanced gastrointestinal stromal tumors (GIST).
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Next-generation sleep diagnostics, integrating AI, wearables, and sensors, promise to redefine the care continuum for sleep disorders, moving beyond traditional polysomnography.
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
EHA 2026 discussions highlight persistent challenges in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) management, focusing on optimal sequencing and novel agent integration.
XLH Management: Rheumatology Must Adapt at EULAR 2026
Current rheumatology approaches for rare bone diseases like X-linked hypophosphatemia (XLH) require re-evaluation. EULAR 2026 presents an opportunity to integrate multidisciplinary care models.
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
Chemotherapy-free regimens for pediatric acute promyelocytic leukemia (APL) demonstrate superior efficacy and reduced toxicity compared to traditional chemotherapy.
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
EASL 2026 highlights the evolving role of non-invasive diagnostics in liver disease, offering improved accuracy for fibrosis and steatosis assessment.
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
EULAR 2026 highlights the critical role of rapid disease control in systemic lupus erythematosus (SLE) to mitigate irreversible organ damage.
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
Bispecific antibodies offer new options for relapsed/refractory follicular lymphoma, particularly after two prior lines of therapy.
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
New A-TANGO organ failure score refines acute-on-chronic liver failure (ACLF) diagnosis and prognostication in hospitalised cirrhosis patients.
Macrophages: Dual Role in Haematological Malignancies Explored
Macrophages exhibit a dual role in haematological malignancies, acting as both tumour suppressors and promoters, influencing disease progression and therapeutic responses.
